Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:AVDL NASDAQ:IBB NASDAQ:SANA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$7.98+0.6%$9.74$7.21▼$22.37$1.85B0.836.32 million shs3.10 million shsAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsIBBiShares Biotechnology ETF$172.180.0%$169.35$120.33▼$179.64$8.18B0.731.36 million shs1.41 million shsSANASana Biotechnology$3.30+5.4%$3.23$2.10▼$6.55$918.36M2.173.96 million shs5.01 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-3.16%-22.15%-48.75%-59.10%AVDLAvadel Pharmaceuticals0.00%0.00%0.00%0.00%+136.35%IBBiShares Biotechnology ETF0.00%+2.01%+2.07%-1.82%+41.24%SANASana Biotechnology0.00%+7.49%+0.30%-21.62%+46.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$7.98+0.6%$9.74$7.21▼$22.37$1.85B0.836.32 million shs3.10 million shsAVDLAvadel Pharmaceuticals$21.39-1.1%$21.48$8.19▼$23.57$2.09B1.312.03 million shs35.02 million shsIBBiShares Biotechnology ETF$172.180.0%$169.35$120.33▼$179.64$8.18B0.731.36 million shs1.41 million shsSANASana Biotechnology$3.30+5.4%$3.23$2.10▼$6.55$918.36M2.173.96 million shs5.01 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-3.16%-22.15%-48.75%-59.10%AVDLAvadel Pharmaceuticals0.00%0.00%0.00%0.00%+136.35%IBBiShares Biotechnology ETF0.00%+2.01%+2.07%-1.82%+41.24%SANASana Biotechnology0.00%+7.49%+0.30%-21.62%+46.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.20Hold$19.00138.10% UpsideAVDLAvadel Pharmaceuticals 2.00Hold$20.20-5.56% DownsideIBBiShares Biotechnology ETF 2.73Moderate Buy$172.18N/ASANASana Biotechnology 2.67Moderate Buy$9.50187.88% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, IBB, SANA, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/11/2026SANASana Biotechnology Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.005/7/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.005/7/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$24.00 ➝ $20.005/1/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.004/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/14/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026SANASana Biotechnology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $7.004/13/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $24.00(Data available from 5/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M3.63$0.65 per share12.20$1.68 per share4.75AVDLAvadel Pharmaceuticals$248.52M8.41N/AN/A$0.77 per share27.78IBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/A$0.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6811.747.60N/A32.43%39.98%28.08%8/5/2026 (Estimated)AVDLAvadel Pharmaceuticals-$48.83MN/AN/A356.50N/A-0.11%-0.33%-0.15%N/AIBBiShares Biotechnology ETFN/AN/AN/AN/AN/AN/AN/AN/AN/ASANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)Latest AVDL, IBB, SANA, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million3/3/2026Q4 2025SANASana Biotechnology-$0.13-$0.16-$0.03-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AIBBiShares Biotechnology ETF$0.380.22%N/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ALatest AVDL, IBB, SANA, and ADMA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/16/2026IBBiShares Biotechnology ETFQuarterly$0.12180.29%3/17/20263/17/20263/20/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93AVDLAvadel PharmaceuticalsN/A2.762.37IBBiShares Biotechnology ETFN/AN/AN/ASANASana BiotechnologyN/A1.291.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AVDLAvadel Pharmaceuticals69.19%IBBiShares Biotechnology ETF62.45%SANASana Biotechnology88.23%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%AVDLAvadel Pharmaceuticals5.20%IBBiShares Biotechnology ETFN/ASANASana Biotechnology25.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableAVDLAvadel Pharmaceuticals7097.66 million92.58 millionOptionableIBBiShares Biotechnology ETFN/A47.50 millionN/AOptionableSANASana Biotechnology380278.29 million207.61 millionOptionableAVDL, IBB, SANA, and ADMA HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Sana Biotechnology (NASDAQ:SANA) to "Hold"May 30 at 1:34 AM | americanbankingnews.comSana Biotechnology to Present at June 2026 Investor ConferencesMay 27, 2026 | globenewswire.comSana Biotechnology Raises $69 Million Through Equity OfferingMay 15, 2026 | tipranks.comSana Biotechnology Shares Fall on Sale of $69 Million in Shares Through At-The-Market FacilityMay 15, 2026 | marketwatch.comSana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) FacilityMay 15, 2026 | globenewswire.comSana Biotechnology (SANA) Receives a Buy from WedbushMay 14, 2026 | theglobeandmail.comBank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)May 13, 2026 | theglobeandmail.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell ...May 13, 2026 | markets.businessinsider.comSana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comSana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPsMay 12, 2026 | globenewswire.comSana: Q1 Earnings SnapshotMay 12, 2026 | finance.yahoo.comSana Biotechnology Reports First Quarter 2026 Financial Results and Business UpdatesMay 12, 2026 | markets.businessinsider.comRodman & Renshaw Begins Coverage on Sana Biotechnology (NASDAQ:SANA)May 11, 2026 | marketbeat.comSana Biotechnology (NASDAQ:SANA) Rating Increased to Sell at Wall Street ZenMay 9, 2026 | marketbeat.comSana Biotechnology (SANA) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comSana Biotechnology to Present at the BofA Securities 2026 Healthcare ConferenceMay 5, 2026 | globenewswire.comSana to present in vivo CAR T data as Janux drops trialApril 28, 2026 | msn.comSana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingApril 27, 2026 | globenewswire.comSana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 DiabetesApril 27, 2026 | finance.yahoo.comSana Biotechnology Rebalances Board Classes With Director ShiftApril 24, 2026 | tipranks.comAssessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity InvestmentApril 23, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026Norwegian Cruise Line Cuts Outlook as Headwinds BuildBy Jennifer Ryan Woods | May 5, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026AVDL, IBB, SANA, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$7.98 +0.05 (+0.63%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$8.05 +0.07 (+0.88%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Avadel Pharmaceuticals NASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.iShares Biotechnology ETF NASDAQ:IBB$172.18 -0.06 (-0.03%) As of 05/29/2026 04:00 PM EasterniShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.Sana Biotechnology NASDAQ:SANA$3.30 +0.17 (+5.43%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$3.32 +0.03 (+0.76%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
